4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Abstract

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.

1 - 56 . (canceled) 
     
     
         57 . A compound of Formula (II): 
       
         
           
           
               
               
           
         
       
       wherein
 X is selected from a covalent bond, S, or O; 
 Y is S or O; 
 —W— represents a group selected from —CH═, —CH 2 —, —CH 2 —CH 2 —, —CH 2 —CH═, and —CH═CH—; 
 Z is selected from O, CH, and CH 2 , provided when Y is O, Z is O; 
 R 1  and R 2  are independently selected from H, C 1-3  alkyl, C 1-3  alkoxy, halo, and NR a R b  wherein R a  and R b  are independently H or C 1-3  alkyl; 
 R 3  and R 4  are independently selected from H, halo, cyano, hydroxy, acetyl, C 1-5  alkyl, C 1-4  alkoxy, and NR c R d  wherein R c  and R d  are independently H or C 1-3  alkyl, provided that R 3  and R 4  are not both H; 
 n is 1 or 2; 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
         58 . The compound of  claim 57  wherein X is S or O. 
     
     
         59 . The compound of  claim 58  wherein X is O. 
     
     
         60 . The compound of  claim 57  wherein X is a covalent bond. 
     
     
         61 . The compound of  claim 57  wherein Y is O. 
     
     
         62 . The compound of  claim 57  wherein Y is S. 
     
     
         63 . The compound of  claim 57  wherein Z is O. 
     
     
         64 . The compound of  claim 57  wherein Z is CH or CH 2 . 
     
     
         65 . The compound of  claim 57  wherein —W— represents —CH 2 — or —CH 2 —CH 2 —. 
     
     
         66 . The compound of  claim 65  wherein —W— represents —CH 2 —. 
     
     
         67 . The compound of  claim 57  wherein —W— represents —CH═, —CH 2 —CH═, or —CH═CH—. 
     
     
         68 . The compound of  claim 57  wherein R 3  and R 4  are independently selected from H, halo, cyano, C 1-4  alkyl, and C 1-3  alkoxy. 
     
     
         69 . The compound of  claim 57  wherein R 1  and R 2  are independently selected from H, C 1-3  alkyl, C 1-3  alkoxy, F, Cl, and Br. 
     
     
         70 . The compound of  claim 69  wherein R 1  and R 2  are independently selected from H, methyl, methoxy, F and Cl. 
     
     
         71 . The compound of  claim 57  wherein R 3  and R 4  are independently selected from H, halo, cyano, hydroxy, C 2-4  acyl, C 1-4  alkyl, and C 1-3  alkoxy. 
     
     
         72 . The compound of  claim 71  wherein R 3  is independently selected from H, F, Cl, methyl, and methoxy. 
     
     
         73 . The compound of  claim 71  wherein R 4  is independently selected from F, Cl, methyl, methoxy, trifluoromethyl, fluoromethyl, difluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, fluoromethoxy, difluoromethoxy, chlorodifluoromethoxy, dichlorofluoromethoxy and trifluoromethoxy. 
     
     
         74 . The compound of  claim 57  wherein R 3  is selected from methyl, methoxy, H, Cl, Br, I, OH, —CH(CF 3 ) 2 , CF 3 , —OCF 3 , —N(CH 3 ) 2 , —O—CH 2 COOH, and —COCH 3 , and R 4  is selected from H, Cl, and methyl. 
     
     
         75 . The compound of  claim 57  wherein R 3  is selected from H, F, Cl, methyl, and methoxy, and R 4  is selected from F, Cl, methyl, fluoromethyl, difluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethyl, trifluoromethoxy, and methoxy. 
     
     
         76 . The compound of  claim 57  wherein R 1  is selected from H, CF 3 , methyl, Cl, and methoxy, and R 2  is selected from H, Cl, and methyl. 
     
     
         77 - 92 . (canceled) 
     
     
         94 . A pharmaceutical composition comprising a compound of  claim 57 . 
     
     
         95 . (canceled)